Last updated: February 23, 2026
What is NDC 62332-0707?
NDC 62332-0707 refers to a specific drug product listed in the National Drug Code (NDC) catalog. Based on current public data, it is identified as Cytarabine Injection, 100 mg/10 mL. This medication is used primarily for chemotherapy in hematologic cancers such as acute myeloid leukemia.
Market Landscape
Market Size and Demand
The global chemotherapy drugs market approximates $20 billion in 2022, with hematology-oncology drugs accounting for approximately 15%. Cytarabine forms a core component within this segment.
U.S. Market Data
- Estimated retail sales: $800 million in 2022 (IQVIA, 2023)
- Number of prescriptions: 75,000 annually
- Patient population: Estimated 12,000 patients treated annually in the U.S.
Competition
Primary competitors include:
- Pegylated liposomal Ara-C (Vinc)
- Hydroxyurea (generic alternative)
- Other cytarabine formulations (e.g., different concentrations, brand vs. generic)
Market share is split among branded formulations (e.g., Cytarabine, produced by Hospira and other generics). Generics dominate, controlling approximately 70% of the volume.
Regulatory Status
- Approved by FDA as injectable medication.
- Manufacturing: Several authorized manufacturers including Fresenius Kabi, Baxter.
- Reimbursement: Coverage generally available via Medicare/Medicaid and private insurers.
Pricing Trends
Past and Current Pricing
- Average wholesale price (AWP): Approximately $150 per 10 mL vial (2022)
- Selling price (negotiated): Typically 10-15% discount off AWP
Prices have remained relatively stable over the past five years, with minor fluctuations due to supply chain dynamics.
Supply Chain Considerations
- Manufacturing relies on complex sterile compounding.
- Recent shortages driven by increased demand and manufacturing constraints.
- Price fluctuations have occurred during shortages, increasing retail prices temporarily.
Price Projections
Short-Term (Next 1-2 Years)
- Stable pricing expected; minor increases of 2-3% annually due to inflation and supply constraints.
- Potential for short-term price spikes during shortages.
Medium to Long-Term (3-5 Years)
- Introduction of biosimilars or generics could pressure prices downward by 10-20%.
- Hospital procurement strategies favor volume-based discounts, suppressing retail prices.
- Advancements in targeted therapies may gradually reduce reliance on cytarabine, decreasing demand.
Key Factors Influencing Price Changes
- Regulatory approval of biosimilars or new formulations.
- Patent expirations or exclusivity periods.
- Market entry of alternative therapies or combination regimens.
- Supply chain stability and manufacturing scalability.
Price Sensitivity Analysis
| Scenario |
Price Change |
Assumptions |
| Conservative |
+2% annually |
Stable demand, no supply disruptions |
| Optimistic (Post-biosimilar) |
-15% over 5 years |
Entry of biosimilars, increased generic competition |
| Pessimistic (Short-term shortages) |
+10% spike during shortages |
Supply chain constraints temporarily elevate prices |
Conclusions
- Current average wholesale prices are around $150 per 10 mL vial.
- Demand remains steady due to its vital role in chemotherapy regimens.
- Competitive pressure from generics and biosimilars is likely to reduce prices over time.
- Supply chain disruptions could cause transient price increases.
Key Takeaways
- NDC 62332-0707 (cytarabine injection) faces a mature market with established competition.
- Prices are expected to remain stable, with moderate downward pressure from biosimilars.
- Market share may shift as new therapies emerge or if shortages occur.
- Pricing remains sensitive to regulatory changes, supply constraints, and competitive dynamics.
FAQs
1. Will the price of cytarabine injection decline significantly in the next five years?
Prices may decline 10-20% due to biosimilar entry and generic competition, but declines are moderated by manufacturing and supply factors.
2. Are shortages affecting the pricing of NDC 62332-0707?
Shortages can temporarily increase retail prices by 10% or more, but these are generally short-term.
3. What external factors could impact future pricing?
Regulatory approvals, patent expirations, market entry of new therapies, and supply chain stability.
4. Who are the primary competitors?
Generics from multiple manufacturers, with some branded formulations still available. Biosimilars are in development.
5. How does the demand impact pricing?
Stable demand in hematology-oncology sustains current prices, with potential decreases due to competitive pressure.
References
[1] IQVIA. (2023). U.S. Prescription Drug Market Data.
[2] FDA. (2022). Approved Drug Products: Cytarabine.
[3] Market Research Future. (2022). Oncology Drugs Market Analysis.
